Literature DB >> 3891365

Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease.

A M Carella, G Santini, A Santoro, P Coser, F Frassoni, M Martinengo, S Nati, A Congiu, D Giordano, R Cerri.   

Abstract

A group of 13 patients with advanced, diffuse Hodgkin's disease, poorly responding to the most widely employed primary chemotherapy regimens, were treated with massive chemotherapy (MCH) followed by rescue with non-frozen autologous bone marrow infusion (ABMT). Complete remission (CR) was obtained in 8/13 patients (61.5%) and partial remission in two. Hematopoietic recovery occurred in 12 cases. These preliminary results would seem to indicate that MCH with non-frozen ABMT may be successfully used in patients with resistant or relapsed Hodgkin's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3891365     DOI: 10.1016/0277-5379(85)90089-6

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  6 in total

1.  Hematopoietic reconstitution after high-dose chemotherapy and autologous nonfrozen bone marrow rescue.

Authors:  H Köppler; K H Pflüger; K Havemann
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

2.  Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.

Authors:  V Diehl; M Pfreundschuh; M Löffler; U Rühl; E Hiller; H Gerhartz; W Wilmanns; H Kirchner; W Schoppe; S Petsch
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 3.  High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

Authors:  Oscar B Lahoud; Craig S Sauter; Paul A Hamlin; Parastoo Bahrami Dahi
Journal:  Curr Oncol Rep       Date:  2015-09       Impact factor: 5.075

4.  Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group.

Authors:  M Loeffler; M Pfreundschuh; D Hasenclever; E Hiller; H Gerhartz; W Wilmanns; R Rohloff; U Rühl; G Kühn; R Fuchs
Journal:  Blut       Date:  1988-06

Review 5.  Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma.

Authors:  Parastoo B Dahi; Hillard M Lazarus; Craig S Sauter; Sergio A Giralt
Journal:  Bone Marrow Transplant       Date:  2018-11-02       Impact factor: 5.174

6.  Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

Authors:  L K Seymour; R D Dansey; W R Bezwoda
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.